Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

Click to increase image sizeClick to decrease image size

Acknowledgments

The Lymphoma Research Foundation hosts Lymphoma Rounds, a national professional education program series in Boston, Chicago, Los Angeles, New York, Philadelphia, San Francisco, Seattle and Washington, DC.

Case reports are edited by Koen Van Besien, MD, PhD and Morton Coleman, MD.

This case was presented at Lymphoma Rounds in New York City.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2019.1594220.

Additional information

Funding

Dr. Horwitz reports grants and personal fees from ADCT Therapeutics, grants and personal fees from Aileron, personal fees from Corvus, grants and personal fees from Forty Seven, personal fees from Innate Pharma, grants and personal fees from Kyowa Hakka Kirin, grants and personal fees from Millennium/Takeda, personal fees from Miragen, personal fees from Mundipharma, personal fees from Portola, grants and personal fees from Seattle Genetics, personal fees from Beigene, personal fees from Affirmed, grants from Celgene, grants from Infinity/Verastem, grants from Trillium, outside the submitted work.